









































































It should be emphasised that in any case the use of Pandemrix in place of a seasonal influenza vaccine is hypothetical, as currently no doses of Pandemrix remain on the market and the MAH has no plans to manufacture any further batches.

On the basis of their assessment considering Pandemrix use in a seasonal context, which is at least a theoretical possibility, the MAH now agrees to the previous CHMP proposal to restrict the indication of Pandemrix to state that it should only be used if the recommended annual seasonal influenza vaccines are not available, and if immunisation against (H1N1)v is considered necessary.

Regarding research into a potential mechanism for the Pandemrix and narcolepsy association, of molecular mimicry involving epitopes on hypocretin neurons and the H1N1 antigen, which is mentioned by the MAH, this will be discussed in the context of an upcoming assessment to the CHMP following the MAH's submission of an updated narcolepsy investigation program in variation II-74.

### **2.3. Risk management plan**

The MAH submitted with this variation application version 17 of the Pandemrix RMP. The RMP includes an updated discussion of narcolepsy with data from Swedish, Finnish and French adult studies, high-level results from the non-clinical research to evaluate potential H1N1/human shared CD4 T cells epitopes (molecular mimicry), details of the updated benefit-risk assessment for Pandemrix, and changes relating to the proposed restricted indication to adults  $\geq 18$  years in a pandemic situation.

In addition, the RMP has been further updated related to the study assessed in variation II/67, concerning results of a self-controlled case series in CPRD on the potential risk of transplant rejection following Pandemrix and II/68, concerning results of the additional test-negative case-control analysis from the Quebec narcolepsy study. The PRAC considered during its March 2014 meeting that the MAH should submit an updated version of the RMP to reflect the requests for revisions to the product information from variation II-69. The updated RMP (version 18) is currently under assessment within variation II/74 (Update of the MAH's research plan reflected in Annex II to conduct non-clinical (including mechanistic) studies in order to elucidate the role of the vaccine and its adjuvant on the association between Pandemrix and narcolepsy).

### **2.4. Changes to the Product Information**

As a result of the re-assessment of the benefit-risk and restriction of the indication, the MAH initially proposed the following changes to the Product Information (PI):

#### **SmPC**

- **Section 4.1:** Reflection of restriction of indication to adults  $\geq 18$  years and only in an officially declared pandemic situation

*Prophylaxis of influenza in adults 18 years of age and older in an officially declared pandemic situation caused by A (H1N1)v 2009 virus. ~~In persons under 20 years of age, Pandemrix should only be used if the recommended annual seasonal trivalent influenza vaccine is not available and if immunisation against (H1N1)v is considered necessary (see sections 4.4 and 4.8).~~*

- **Section 4.2:** Removal of dosing information relating to children and adolescents, addition of a statement that Pandemrix is not recommended in children and adolescents aged below 18 years.
- **Section 4.4:** removal of information relating to the paediatric population (paragraph on intensity of side effects such as fever after second dose) and revision of paragraph on the risk of narcolepsy:

*'Epidemiological studies relating to Pandemrix in several European countries have reported an association between Pandemrix and narcolepsy indicated a five to 14-fold increased risk of narcolepsy with or without cataplexy. These studies have described an absolute risk increase of narcolepsy of approximately 1.4 to 8*

additional cases per 100,000 vaccinated children/adolescents and approximately 1 additional case per 100,000 vaccinated adults compared to background rates of 0.12 to 0.79 per 100,000 children/adolescents per year and 0.67 to 1.10 per 100,000 adults per year. Further research is needed to investigate the observed association between Pandemrix and narcolepsy.  
~~in vaccinated as compared with unvaccinated children/adolescents, corresponding to an absolute risk ranging from three to seven additional cases in 100 000 vaccinated subjects. This risk increase has not been found in adults (older than 20 years).~~

~~The relationship between Pandemrix and narcolepsy is still under investigation.  
 In persons under 20 years of age, Pandemrix should only be used if the recommended annual seasonal trivalent influenza vaccine is not available and if immunisation against (H1N1)v is considered necessary. (see section 4.8)~~

The MAH explained that for the sake of simplicity, only the absolute risk of narcolepsy per 100,000 are retained in the proposal for section 4.4 as they consider this to be the most clinically relevant information. The MAH also proposes to include background incidence rates to provide a baseline for the additional cases of narcolepsy reported. The MAH explains that these rates were taken from a publication by Wijnan et al. (Vaccine. 2013).

- **Section 4.8:** Removal of information on adverse effects in the paediatric population (febrile convulsions, tables of ADRs from clinical studies).
- **Section 5.1:** Removal of paediatric immunogenicity data
- **Annex II:** removal of the commitment to perform a re-analysis of the Quebec narcolepsy dataset with adjustment for medically-attended respiratory infection/influenza like illness.

Description	Due Date
Conduct a retrospective epidemiological study in Canada (Quebec) and follow-up cases to assess any atypical or differential clinical course and prognosis in any vaccinated vs. non-vaccinated subjects: <ul style="list-style-type: none"> <li>- Test-negative case-control study results               <ul style="list-style-type: none"> <li><del>Re-analysis of the dataset with adjustment for medically-attended respiratory infection/influenza-like illness</del></li> </ul> </li> <li>- Re-analysis of the dataset after exclusion of symptomatic controls after 1 year follow-up (if applicable); and description of the clinical follow-up of cases for 2 years.</li> </ul>	December 2013 <del>December 2013</del> December 2014
Conduct non-clinical (including mechanistic) studies in order to elucidate the role of the vaccine and its adjuvant on the association between Pandemrix and narcolepsy: <ul style="list-style-type: none"> <li>- If deep sequencing approach is proven feasible:               <ul style="list-style-type: none"> <li>o identify T cell signature from narcoleptic patients and, if identified, verify if signature is found in CD4 T cells from healthy vaccinees</li> <li>o if identified, verify if T cell signature is detected in influenza-specific CD4 T cells from narcoleptic patients</li> </ul> </li> <li>- Establish influenza-specific T cell lines to evaluate potential cross-reactivity with hypocretin peptides, with identified DQ*0602 binders and with additional proteins using T2 cells as antigen-presenting cells</li> <li>- Conduct a study in cotton rats to evaluate the potential impact of Pandemrix vaccination/H1N1v infection on the blood-brain-barrier integrity and CNS inflammation/damage.</li> <li>- Evaluate the potential for immunological differences between Pandemrix and Arepanrix H1N1 using antibody avidity analysis and phage display-assisted epitope mapping from clinical serum samples obtained before and at Day 21 after vaccination from clinical studies in which the two vaccines were compared.</li> </ul>	June 2014 December 2014 December 2014 June 2014 December 2014

During the procedure, the CHMP did not accept the MAH's initial proposal for the restriction of the indication and requested additional amendments to the Product Information. The premise of the MAH's quantitative benefit assessment and proposed indication, i.e. that Pandemrix may offer benefits in a future pandemic, was considered invalid by the CHMP. This assessment can only be undertaken on the basis of the currently approved indication. As no new data have been presented that would affect the potential, benefits of the vaccine to individuals (notwithstanding the fact that the vaccine is no longer in use and TIV/QIV are the vaccines of choice), and as no significant new data have been presented on the attributable risk of narcolepsy, there is little basis to alter the current conclusion on the indication as reached by PRAC / CHMP in June 2013.

Therefore, the MAH's proposal for section 4.1, and hence, the proposal to remove all paediatric data from the product information was not accepted.

Moreover, the MAH's proposal for section 4.4 was not considered to be justified and therefore the MAH was requested to adopt the narcolepsy paragraph proposed by the PRAC /CHMP in June 2013, with some amendments to the risk estimates. The MAH was also requested to amend section 2 of the PL in accordance with the requested SmPC revisions.

As discussed above, the MAH agreed to amend the wording of the Pandemrix indication to restrict its use as a seasonal vaccine only if seasonal influenza vaccines are not available, as requested by the CHMP in June 2013. The minor modification to include reference to quadrivalent seasonal influenza vaccines is accepted.

In addition, The MAH agreed to the PRAC-proposed wording for section 4.4 of the Pandemrix SmPC. The rationale for the slight amendment to the statement on declining risk with increasing age at vaccination is acknowledged, and the modification is accepted.

The proposal to add reference to seasonal quadrivalent influenza vaccines in the context of availability of seasonal vaccines is agreed.

Although not discussed in the MAH's responses, as per the CHMP request from June 2013, the MAH has removed from section 4.8 of the SmPC, the footnote to table of ADRs which indicates that narcolepsy has only been reported in those below 20 years, which is considered acceptable.

The MAH has also adopted the wording requested by CHMP for the package leaflet to reflect the SmPC changes accordingly.

The proposal to remove from Annex II, the commitment to perform a re-analysis of the Quebec narcolepsy dataset with adjustment for medically-attended respiratory infection/influenza like illness is also accepted.

Please refer to attached highlighted version of the product information for further details.

### **3. Overall conclusion and impact on the benefit/risk balance**

As requested by the CHMP in March 2014, the MAH submitted in the context of this type II variation, a benefit-risk assessment of Pandemrix when used in a hypothetical scenario as a seasonal vaccine for prophylaxis against A (H1N1)09-related infections and proposed to update the Pandemrix product information to reflect the totality of epidemiological evidence on the association between the vaccine and narcolepsy.

Notwithstanding that only a qualitative assessment has been provided due to lack of data on Pandemrix use as a seasonal influenza vaccine (although the indication permits seasonal use, the vaccine had not been used since 2011 and all doses on the market expired some time ago), involving a range of assumptions from level of disease burden to vaccine uptake, it is acknowledged that the A (H1N1)09 continues to circulate globally and contribute to a substantial amount of the disease burden associated with influenza infection. It is also acknowledged that available immunogenicity and efficacy data for Pandemrix support the beneficial effects that this vaccine could offer the general population in the event of unavailability of alternative seasonal tri- and quadrivalent influenza vaccines, in particular for certain vulnerable populations (pregnant women, the elderly and immunocompromised individuals). The main risk associated with Pandemrix is that of narcolepsy, with epidemiological studies suggesting a vaccine attributable risk 1 to 8 additional cases per 100,000 persons.

As a result of the MAH's additional benefit-risk assessment, the MAH agrees to the CHMP proposed revisions to the Pandemrix SmPC and PIL (to remove the age restriction of 20 years from section 4.1, to remove the sentence on [no increased risk of] narcolepsy in adults and to revise the narcolepsy warnings to reflect the current totality of epidemiological data on Pandemrix and narcolepsy). The MAH also proposed some minor modifications to the wording which is accepted. Taking into account the safety data submitted and their reflection in the Product Information in terms of a restriction of the indication, the CHMP considers that the benefit-risk balance for Pandemrix is favourable in the restricted indication.

## 4. Recommendations

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation(s) to the terms of the Marketing Authorisation, concerning the following change(s):

Variation(s) requested		Type
C.I.6.a	C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one	II

To revise the indication to reflect that Pandemrix should only be used for prophylaxis of influenza caused by A(H1N1)v 2009 if recommended seasonal influenza vaccine is not available and immunisation against A(H1N1)v 2009 is considered necessary, to update sections 4.4 and 4.8 of the SmPC to reflect the totality of the data on the risk of narcolepsy and to provide an updated benefit-risk assessment of Pandemrix, based on the data currently available to the MAH on H1N1 influenza disease burden, effectiveness and safety of Pandemrix and available epidemiology data on narcolepsy. The Package Leaflet is updated accordingly.

The MAH also took the opportunity to update the list of 'Obligation to conduct post-authorisation measures' in Annex II to remove the condition "Re-analysis of the dataset with adjustment for medically-attended respiratory infection/influenza-like illness" as the MAH will not be in a position to fulfil this request.

The requested variation proposed amendments to the Summary of Product Characteristics, Annex II and Package Leaflet.

### **Conditions and requirements of the marketing authorisation**

- **Obligation to conduct post-authorisation measures**

The MAH shall complete, within the stated timeframe, the below measures:

Description	Due Date
Conduct a retrospective epidemiological study in Canada (Quebec) and follow-up cases to assess any atypical or differential clinical course and prognosis in any vaccinated vs. non-vaccinated subjects: <ul style="list-style-type: none"> <li>- Test-negative case-control study results</li> <li>- Re-analysis of the dataset after exclusion of symptomatic controls after 1 year follow-up (if applicable); and description of the clinical follow-up of cases for 2 years.</li> </ul>	December 2013  December 2014
Conduct non-clinical (including mechanistic) studies in order to elucidate the role of the vaccine and its adjuvant on the association between Pandemrix and narcolepsy: <ul style="list-style-type: none"> <li>- If deep sequencing approach is proven feasible:               <ul style="list-style-type: none"> <li>o identify T cell signature from narcoleptic patients and, if identified, verify if signature is found in CD4 T cells from healthy vaccinees</li> <li>o if identified, verify if T cell signature is detected in influenza-specific CD4 T cells from narcoleptic patients</li> </ul> </li> <li>- Establish influenza-specific T cell lines to evaluate potential cross-reactivity with hypocretin peptides, with identified DQ*0602 binders and with additional proteins using T2 cells as antigen-presenting cells</li> <li>- Conduct a study in cotton rats to evaluate the potential impact of Pandemrix vaccination/H1N1v infection on the blood-brain-barrier integrity and CNS inflammation/damage.</li> <li>- Evaluate the potential for immunological differences between Pandemrix and Arepanrix H1N1 using antibody avidity analysis and phage display-assisted epitope mapping from clinical serum samples obtained before and at Day 21 after vaccination from clinical studies in which the two vaccines were compared.</li> </ul>	June 2014  December 2014 December 2014  June 2014  December 2014

## 5. References

- Ahmed I, Thorpy M. Clinical features, diagnosis and treatment of narcolepsy. Clin Chest Med 2010;31:371-81.
- Ahout I, Ferwerda G, deGroot R. Influenza vaccination in kids, are you kidding me? Journal of Infection 2014; 68: S100-S107.
- Andrews N, Wright P, Yung CF, Miller E. Age specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis 2011; 203(1): 32-39.
- Aran A et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009; 32: 979-983.
- Arriola CS. Update: Influenza Activity — United States, September 29, 2013–February 8, 2014 MMWR / February 21, 2014 / Vol. 63 / No. 7.
- Altamirano-Diaz L, West L, Humar A, Ely L, Urschel S, Gubbay J, Crowcroft N, Kumar D. Early posttransplant vaccination with pandemic influenza A/ H1N1 vaccine in pediatric heart transplant recipients. Pediatric Transplantation 2011; 15 (2): 172-175.

Avery RK. Influenza vaccines in the setting of solid organ transplantation: are they safe? *Curr Opin Infect Dis* 2012; 25: 464-468.

Bardage, C., et al., Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. *BMJ*, 2011. 343: p. d5956.

Brakemeier S, Schweiger B, Lachmann N et al. Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix™) in renal transplant recipients. *Nephrol Dial Transplant* 2012; 27:1 (423-428).

Broeders NE, Hombrouck A, Lemy A, Wissing KM, Racapé J et al. Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: A cohort study. *Clin J Am Soc Nephrology* 2011; 6 (11): 2573-2578.

Candon S, Thervet E, Lebon P et al. Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. *Am J Transplant* 2009; 9:2346-2354.

Carmona A, Omenaca F, Tejedor JC, Merino JM, Vaman T, Dieussaert et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. *Vaccine* 2010 ; 28 :5837-44.

Castilla J, Morn J, Martínez-Artola V, Fernández-Alonso M et al. Effectiveness of the monovalent influenza A (H1N1)2009 vaccine in Navarre, Spain, 2009-2010: Cohort and case-control study. *Vaccine* 2011; 29: 5919-5924.

Catania J. High intensive care unit rate for 2013-2014 influenza is associated with a low rate of vaccination. *American Journal of Respiratory and Critical Care Medicine* 2014; 189 (4): 4850486.

Chabas D, Taheri S, Renier C, Mignot E. The genetics of narcolepsy. *Annu Rev Genomics Hum Genet.* 2003; 4:459-83.

CDC. Prevention and Control of Seasonal Influenza with vaccines. Recommendations of the Advisory Committee on Immunization practices United States, 2013-2014. *MMWR* September 20, 2013; 62(7).

Centers for Disease Control and Prevention (CDC). Use of Influenza A (H1N1) 2009 Monovalent Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. *MMWR* August 28 2009; 58( RR10);1-8

Cordero E, Manuel O. Influenza vaccination in solid-organ transplant recipients. *Curr Opin Organ Transplant.* 2012; 17(6): 601-608.

Costa JT, Silva R, Tavares M, Nienhaus A. High effectiveness of pandemic influenza A (H1N1) vaccination in healthcare workers from a Portuguese hospital. *International Archives of Occupational and Environmental Health* 2012; 85 (7): 747-752.

Crespo M, Collado S, Mir M, Cao H, Barbosa F, Serra C et al. Efficacy of influenza A H1N1/2009 vaccine in hemodialysis and kidney transplant patients. *Clinical Journal of the American society of Nephrology* 2011; 6: 2208-2214.

Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. *Lancet* 2007;369:499-511.

Dauvilliers Y, Montplaisir J, Molinari N et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. *Neurology* 2001; 57(11): (2029-2033).

Dauvilliers, Y., et al., Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. *Brain*, 2013. 136(Pt 8): p. 2486-96.

Dawood FS. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modeling study. *The Lancet Infectious Diseases* 2012; 12(9):687-695.

De Diego C, Vila-Córcoles A, Ochoa O, Rodriguez-Blanco T, Salsench E, Hospital I, Bejarano F, del Puy Muniain M, Fortin M, Canals M and EPIVAC Study Group. Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease. *Europ Heart J* 2009; 30:209-16.

Demicheli V, Jefferson T, Al-Ansary LA, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. *Cochrane Database of Systematic Reviews* 2014, Issue 3. Art. No.: CD001269. DOI: 10.1002/14651858.CD001269.pub5. *Euroflu Bulletin Review* 07 January 2011, no 383. [http://euroflu.org/cgi-files/bulletin\\_v2.cgi](http://euroflu.org/cgi-files/bulletin_v2.cgi).

Dieleman J, Romio S, Johansen K, Wiebel D, Bonhoeffer J, Sturkenboom M. Guillain-Barré Syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. *BMJ* 2011; 343: d3908 doi: 10.1136/bmj.d3908.

Duncan IG, Taitel MS, Zhang J, Kirkham HS. Planning influenza vaccination programs: a cost benefit model. *Cost effectiveness and resource allocation* 2012; 10 (10).

ECDC, Narcolepsy in association with pandemic influenza vaccination. A multi-country European epidemiological investigation., 2012: Stockholm.

ECDC. Weekly influenza surveillance report 11 April 2014. Accessed 16 April 2014. <http://www.ecdc.europa.eu/en/publications/Publications/influenza-surveillance-overview-11-april-2014.pdf>

Emborg H-D, Krause TG, Hviid A, Simonsen J, Mølbak K. Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009-10. *BMJ* 2011; 344:d7901 doi: 10.1136/bmj.d7901.

European Centre for Disease Prevention and Control. Seasonal influenza 2013-2014 in the EU/EEU countries. Stockholm: ECDC; 2014.

Fell DB, Sprague AE, Liu N, Yasseen AS 3rd, et al. H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes. *Am J Public Health* 2012 Jun; 102 (6):e33-40.

Goldschmidt I, Pfister ED, Becker M, Hackl S, Bott OJ, Baumann U, Baumann U. Acceptance and Adverse events of the 2009 H1N1 vaccination in immunosuppressed pediatric liver transplant recipients. *The Journal of Pediatrics* 2011; 158 (2): 329-333.

Håberg SE, Trogstad L, Gunnes N, Wilcox AJ, Gjessing HK, et al. Risk of fetal death after pandemic influenza virus infection or vaccination. *NEJM* 2013; 368:333-340.

Han F, Lin L, Li J, Dong SX, An P, et al. HLA-DQ association and allele competition in Chinese narcolepsy. *Tissue antigens* 2012; 80:328-335.

Han F, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. *Ann Neurol* 2011; 70(3): 410-7.

Han F, Lin L, Li J, Dong XS, Mignot E. Decreased incidence of childhood narcolepsy 2 years after the 2009 H1N1 winter flu pandemic. *Ann Neurol*. 2012 Nov 9. doi: 10.1002/ana.23799

Hardelid P, McMenamin J, Andrews N, et al. Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A (H1N1) 2009 infection in England and Scotland 2009-2010. *Eurosurveillance* 2011; 16(6): pii=19791.

Hauser IA, Roessel D, Gauer S, et al. Efficacy and safety of H1N1 vaccination in renal transplant recipients and chronic dialysis patients. *Am J Transplant* 2011; 11(Supplement 2):286.

Health Protection Surveillance Centre. I-Move influenza vaccine effectiveness study, 2010. Available online: <https://www.hpsc.ie/A-Z/Respiratory/Influenza/SeasonalInfluenza/Publications/InfluenzaVaccinationPublications/File,4511,en.pdf>

Heier, M.S., et al., Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. *Sleep Med*, 2013. 14(9): p. 867-71.

Hellenbrand W, Jorgensen P, Schweiger B, Falkenhorst G, Nachtnebel M et al. Prospective hospital based case-control study to assess the effectiveness of pandemic influenza A (H1N1)pdm09 vaccination and risk factors for hospitalization in 2009-2010 using matched hospital and test-negative controls. *BMC Infect Dis* 2012; 12: 127.

Ingravallo F, Gnucci V, Pizza F, Vignatelli L, Govi A, Dormi A, Pelottis S, Cicognani A, Dauvilliers Y, Plazzi G. The burden of narcolepsy with cataplexy: how disease history and clinical features influence socio-economic outcomes. *Sleep Medicine* 2012; 13: 1293-1300.

INSERM, Etude NarcoFlu-VF. (NarcoFlu VAESCO-France) Rapport Final, 2012.

Ireland, D., Final Report of the National Narcolepsy Study Steering Committee, 2012, DOH Ireland: Dublin.

Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E. Vaccines for preventing influenza in healthy children. *Cochrane Database of Systematic Reviews* 2012, Issue 8. Art. No.: CD004879. DOI: 10.1002/14651858.CD004879.pub4.

Katerinis I, Hadaya K, Duquesnoy R, Ferrari-Lacraz S, Meier S et al. De Novo Anti-HLA after Pandemic H1N1 and Seasonal Influenza Immunization in Kidney Transplant Recipients. *Am J Transplantation* 2011; 11: 1727-1733.

Kavanaugh K, Robertson C, McMenamin J. Assessment of the variability in influenza A (H1N1) vaccine effectiveness estimates dependent on outcome and methodological approach. *PLoS one* 6(12): e28743. Doi: 10.1371/journal.pone.0028743.

King Jr JC, Lichenstein R, Cummings GE, Magder LS. Impact of influenza vaccination of schoolchildren on medical outcomes among all resident of Maryland. *Vaccine* 2010; 28: 7737-42.

Kornum B, Faraco J, and Mignot E. Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the brain. *Current Opinion in Neurobiology* 2011; 21: 897-903.

Loeb M, Russell, ML, Moss L, Fonseca K, Fox J et al. Effect of influenza vaccination of children on infection rates in Hutterite communities. *JAMA* 2010; 303 (10): 943-950.

Ludvigsson JF, Zugna D, Cnattingius S, Richiardi L, Ekblom A, Örtqvist Å, Persson I, Stephanson O. Influenza H1N1 vaccination and adverse pregnancy outcomes. *Perinatal Epidemiology* 2013; 28: 579-588.

Mahljos J et al. The autoimmune basis of narcolepsy. *Curr Opin Neurobiology* 2013; 23: 767-773.

Mahmud S, Hammond G, Elliott L, Hilderman T, Kurbis C et al. Effectiveness of the pandemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: Population-based case-control study. *Vaccine* 2011; 29: 7975-7981.

McElhaney JE. Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response. *Expert Rev Vaccines* 2009, 8 (5): 593-606.

Memoli MJ, Athota R, Reed S, Czajkowski L, Bristol T et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. *CID* 2014; 58 (2): 214-24.

Mereckiene, J., et al., Influenza A(H1N1)pdm09 vaccination policies and coverage in Europe. *Euro Surveill*, 2012. 17(4).



Meyer S, Adam M, Schweiger B, Ilchmann C, Eulenburg C et al. Antibody response after a single dose of an AS03-adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients. *Transplantation* 2011; 91 (9): 1031-1035.

Mignot E, Lammer GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. *Archives of Neurology* 2002; 59:1553-62

Miller, E., et al., Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. *BMJ*, 2013. 346: p. f794.

Morgenthaler TI, Kapur VK, Brown TM, Sick TJ, Alessi C, et al. Practice parameters for the Treatment of Narcolepsy and other Hypersomnias of central origin. *Sleep* 2007; 30 (12): 1705-1711.

Mosby LG, Rasmussen SA, Jamieson DJ. 2009 Pandemic Influenza A (H1N1) in pregnancy : a systematic review of the literature. *American Journal of Obstetrics and Gynecology* 2011; 205:1 (10-18).

MPA, A registry based comparative cohort study in four Swedish counties of the risk for narcolepsy after vaccination with Pandemrix - A first and preliminary report, by the Medical Products Agency., 2011.

MPA, Registerstudie med fokus på neurologiska och immunrelaterade sjukdomar efter vaccination med Pandemrix, 2013, Läkemedelsverket: Stockholm.

MPA, Report from an epidemiological study in Sweden on vaccination with Pandemrix and narcolepsy, 2011, Läkemedelsverket: Stockholm.

Nair H, Abdullah Brooks W, Katz M, Roca A, Berkley JA, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. *Lancet* 2011; 378:1917-30.

Naresh A (H1N1)09, Fisher BM, Hoppe KK, Catov J et al. A multicenter cohort study of pregnancy outcomes among women with laboratory-confirmed H1N1 influenza. *Journal of Perinatology* 2013; 33(12): 939-943.

Nichol KL, D'Heilly SJ, Greenberg ME, Ehlinger E. Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50-64 years. *Clin Infect Dis* 2009; 48:292-298.

Nohynek, H., et al., AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. *PLoS One*, 2012. 7(3): p. e33536.

Ong BA, Forester J and Fallot A. Does influenza vaccination improve pediatric asthma outcomes? *J Asthma* 2009; 46: 477-80.

Overeem S, Black JL, Lammers GJ. Narcolepsy: immunological aspects. *Sleep Med Rev* 2008; 12:96-107

Örtqvist A, Bennet T, Ryd Rinder M, Lindblad H, Eriksson M. Effectiveness of the monovalent AS03-adjuvanted influenza A(H1N1)pdm09 vaccine against hospitalization in children because of influenza. *Vaccine* 2012; 30: 5699-5702.

Örtqvist A, Berggren I, Insulander M, de Jong B, Svenungsson B. Effectiveness of a monovalent adjuvanted vaccine against the 2009 pandemic strain of influenza A (H1N1)v in Stockholm County, Sweden. *Clin Infect Dis* 2011; 52:1203-1211.

Partinen, M., et al., Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. *PLoS One*, 2012. 7(3): p. e33723.

Pasternak B, Svanström H, Mølgaard-Nielsen D, Krause TG, Emborg HD, Melbye M, et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. *BMJ* (online) 2012; 344: e2794.

Persson I, Granath F., Askling J., Ludvigsson J.F., Olsson T., Feltelius N. Risk of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry based cohort study with over 2 years of follow up., *J Int Med* 2013, 1-17

Pelat C, Falchi A, Carrat F, Mosnier A, Bonmarin I et al. Field effectiveness of pandemic and 2009-2010 seasonal vaccines against 2009-2010 A (H1N1) influenza: estimations from surveillance data in France. *PLoS one* 6 (5):e19621. Doi: 10.1371/journal.pone.0019621.

Pittet LF, Posfay-Barbe KM. Immunization in transplantation: review of the recent literature. *Curr Opin Organ Transplant*. 2013;18(5): 543-548.

Poli F, Overeem S, Lammers GJ, Plaszzi G, Lecendreux M et al. Narcolepsy as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentation. *Vaccine* 2013; 31:994-1007.

Puig-Barbera J, Arnedo-Pena A, Pardo-Serrano F, Tirado-Balaguer MD et al. Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case-control study. *Vaccine* 2010; 28: 7460-7467.

Rambal V, Mueller K, Nickel P, Horstrup J, Friedrich P et al. Evaluation of safety and efficacy of H1N1 swine-origin influenza A vaccination in renal transplant patients. *Nephrology Dialysis Transplantation Plus* 2010 3 (Supplement 3): iii1-iii274.

Reichert, T.A., Simonsen, L., Sharma, A., Pardo, S.A., Fedson, D.S., Miller, M.A., 2004. Influenza and the winter increase in mortality in the United States, 1959–1999. *Am. J. Epidemiol.* 160, 492–502.

Szakacs, A., N. Darin, and T. Hallbook, Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. *Neurology*, 2013. 80(14): p. 1315-21.

Savelescu C, Jimenez-Jorge S, de Mateo S, Pozo F, Casas I et al. Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A (H1N1) 2009 infection: two case-control studies, Spain, season 2009-2010. *BMC Public Health* 2011; 11:899.

Schaffer SA, Kozuszko S, Kavanaugh L, Delgado DH, Ross HJ. Impact of adjuvanted H1N1 vaccine on cell-mediated rejection in heart transplant recipients. Abstract presented at the Canadian Society of Transplantation Annual Scientific Meeting August 2010, Vancouver, British Columbia.

Schuurmans MM, Tini GM, Dalar L, et al. Pandemic 2009 H1N1 influenza virus vaccination in lung transplant recipients: Coverage, safety and clinical effectiveness in the Zurich cohort. *J Heart Lung Transplant* 2011;30(6):685-690.

Siegrist C-A, Ambrosioni J, Bel M, Combescure C, Hadaya K, et al. Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. *Antiviral Therapy* 2012; 17: 893-903.

Simpson CR, Ritchie LD, Robertson C, Sheikh A, McMenemy J. Effectiveness of H1N1 vaccine for the prevention of pandemic influenza in Scotland, UK: A retrospective observational cohort study. *The Lancet Infectious Diseases* 2012; 12 (9): 696-702.

Simpson CR, Ritchie LD, Robertson C, Sheikh A, McMenemy J. Vaccine effectiveness in pandemic influenza – primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. *Health Technology Assessment* 2010; 14 ( 34): 317-346.

Skowronski DM, Janjua NZ, De Serres G, Hottes TS, Dickinson JA, Crowcroft N, Kwit TL, Tang P, Charest H, Fonseca K, Gubbay JB, Bastien N, Li Y, Pedric M. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. *BMJ* 2011;342:c7297.

Tavares F, Nazareth I, Sawchik Monegal J, Kolte I, Verstraeten T, Bauchau V. Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion (2009) pandemic influenza vaccine during pregnancy: A prospective cohort study. *Vaccine* 2011; 29: 6358-6365.

THL, Association between the pandemic vaccine and narcolepsy in adults (Pandemiarokotteen ja narkolepsian yhteys aikuisilla), 2013, Terveystieteiden ja hyvinvoinnin laitos: Helsinki.

THL, National Narcolepsy Task Force Interim Report, 2011: Helsinki

Wijnans L, Lecomte C, de Vries C et al. The incidence of narcolepsy in Europe: Before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. *Vaccine*. 2013; 31: 1246-1254.

Uphoff H, an der Heiden M, Schweiger B, Campe H, Beier D et al. Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A (H1N1) 2009- a comparison of two methods; Germany, 2009/10. *PLoS one* 6 (7): e19932 doi:10.1371/journal.pone.0019932.

Uyeki TM. Preventing and controlling influenza with available interventions. *NEJM* 2014; DOI: 10.1056/NEJMp1400034.

Valenciano M, Kissling E, Cohen J-M, Oroszi B, Barret A-S et al. Estimates of pandemic influenza vaccine effectiveness in Europe (I-MOVE) multicentre case-control study. *PLoS Med* 8(1): e1000388. Doi: 10.1371/journal.pmed.1000388.

VanBuynder PG, Dhaliwal JK, Van Buynder JL, Coutrier C, Minville-LeBlanc M, Garceau R, Tremblay FW. Protective effect of single-dose adjuvanted pandemic influenza vaccine in children. *Influenza and Other Respiratory Viruses* 2010, 4: 171-178

Van Essen GA, Beran J, Devaster J-M, Durand C, Duval X et al. (2014) Influenza symptoms and their impact on elderly adults: randomized trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines. *Influenza and Other Respiratory Viruses* 00 (00), 000- 000.doi:10.1111/irv.12245.

VanKerkove MD, Vandemaele KAH, Shinde V, Jaramillo-Gutierrez G, Koukounari A, et al. Risk factors for severe outcomes following 2009 Influenza A (H1N1) infection: a global pooled analysis. *PLoS Medicine* 2011; 8 (7):e1001053.

Vázquez Álvarez MC, Medrano-López C, Camino- López M. H1N1 influenza infection in pediatric heart transplants. *Eur Heart Journal* 2010; 31 supp.1 (426).

Vila-Córcoles A, Ochoa O, De Diego C, Valdivieso A, Herreros I, Bobe F, Alvarez M, Juárez M, Guinea I, Ansa X, Saún N. Effects of annual influenza vaccination on winter mortality in elderly people with chronic pulmonary disease. *Int J Clin Pract* 2008; 62(1): 10-17.

Vilchez RA, McCurry K, Dauber J et al. Influenza virus infection in adult solid organs transplant recipients. *Am J Transplant* 2002; 2: 287-291.

Weinstock Dm, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. *N Engl J Med* 2003; 348: 867-868.

WHO. Influenza virus infections in humans. 2014a; accessed 09 April, 2014. <http://www.who.int/influenza/vaccines/en/>.

WHO. February 2014. Recommended composition of influenza virus vaccines for use in the 2014-2015 northern hemisphere influenza season. [http://www.who.int/influenza/vaccines/virus/recommendations/2014\\_15\\_north/en/](http://www.who.int/influenza/vaccines/virus/recommendations/2014_15_north/en/) Accessed 09 April 2014.

WHO: Euroflu- weekly electronic bulletin. 28 Feb 2014, issue no. 519. Accessed 16 April 2014. [http://euroflu.org/cgi-files/bulletin\\_v2.cgi](http://euroflu.org/cgi-files/bulletin_v2.cgi)

WHO. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. N Engl J Med 2010; 362: 1708-19.

Wichmann O, Stöcker P, Poggensee G, et al. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany

Medicinal product no longer authorised